

05-18-05


IRW

PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM 		Application Number	10/696,940
		Filing Date	October 30, 2003
		First Named Inventor	Daniel L. Flynn
		Art Unit	Unknown
		Examiner Name	Unknown
Total Number of Pages in This Submission	3	Attorney Docket Number	2932/3A/US 31027/USA (6794-000129/COE)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Form HDP-1449 15 References Return Receipt Postcard
<div style="border: 1px solid black; padding: 5px; min-height: 100px;"> Remarks </div>		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Harness, Dickey & Pierce, P.L.C.		
Signature			
Printed Name	David M. Gryte		
Date	May 17, 2005	Reg. No.	41,809

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	David M. Gryte	Express Mail Label No.	EV 726254443 US
Signature		Date	May 17, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 726254443 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Daniel L. Flynn et al.
Serial No: 10/696,940
Filed: October 30, 2003
For: Electrophilic Ketones for the Treatment of Herpesvirus Infections
Confirmation No: 9087
Group Art Unit: Unknown
Examiner: Unknown
Attorney Ref: 2932/3A/US
Pfizer Ref: 31027/USA
HDP Ref: 6794-000129/US/COE

May 17, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for

relevance every document listed on the attached form even if not initialed.

This application is a divisional of U.S. Application Serial No. 09/712,002 (filed November 14, 2000, now U.S. Patent No. 6,673,784), which, in turn, is a continuation of U.S. Application Serial No. 09/221,016 (filed December 23, 1998, now abandoned), which, in turn, is a continuation of 08/620,681 (filed March 19, 1996, now abandoned). Applicants presume that the Examiner has access to the file histories for the above-referenced applications. Applicants further presume that the Examiner is aware of the issues raised and the scope of claims in those cases, and will take them into account when examining this patent application. Upon request from the Examiner, Applicants can provide copies of the substantive Office actions or any other information relating to those cases, to the extent Applicants have such information in their possession.

Some references cited in this information disclosure statement are U.S. patents or U.S. patent application publications, or were previously cited or submitted to the Office and considered in the above-referenced U.S. applications. Copies of those references are therefore not being provided in accordance with 37 C.F.R. §1.98 and MPEP §609 Part III(A)(2). Applicants, however, will provide copies of such references upon request from the Examiner. The references that are enclosed with this information disclosure statement are identified as being enclosed on the Form 1449.

A concise explanation for the non-English EP 298 020 is provided in the specification on page 2, lines 17-19. Furthermore, an English abstract obtained from <http://ep.espacenet.com> has been filed with this Information Disclosure Statement.

Applicants request early and favorable consideration.

* * * * *

Applicants believe that they do not owe any fee in connection with this information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Information Disclosure Statement
Appl. No. 10/696,940
May 17, 2005

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,




David M. Gryte, PTO Reg. No. 41,809
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **May 17, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**



DMG/jpg/cml
enclosures



MPEP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 4

ATTORNEY DOCKET NO.

2932/3A/US (31027/USA)
(6794-000129/COE)

SERIAL NO.

10/696,940

APPLICANT

Daniel L. Flynn et al.

FILING DATE

October 30, 2003

GROUP

Unknown

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		4,285,943	08/15/1981	Vincent et al.	424/244	
2.		4,855,460	08/08/1989	Tordeux et al.	549/308	
3.		5,071,837	12/10/1991	Doherty et al.	514/18	
4.		5,151,438	09/29/1992	Sham et al.	514/357	
5.		5,166,181	11/24/1992	Cottens	514/653	
6.		5,434,074	07/18/1995	Gibson et al.	435/219	
7.		5,478,727	12/26/1995	Roizman et al.	435/23	
8.		5,608,062	3/04/1997	Doeller et al.	544/238	
9. Notice of Allowance enclosed		6,673,788 (9/09/03 Notice of Allowance enclosed)	01/06/2004	Flynn et al.	514/183	

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
10.		EP 204 571	12/10/1986	Europe	C07C 103/42		
11.		EP 249 349	12/16/1987	Europe	C07D 207/16		
12.		EP 276 101	07/27/1988	Europe	C07K 5/00		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 726254443 US

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 2 of 4</p>	ATTORNEY DOCKET NO.	SERIAL No.
	S02932/3A/US (31027/USA) (6794-000129/COE)	10/696,940
	APPLICANT	
	Daniel L. Flynn et al.	
	FILING DATE	GROUP
	October 30, 2003	Unknown

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No	
13. Abstract enclosed		EP 298 020	01/04/1989	Europe	C07D 301/12	abstract	
14.		EP 337 701	10/18/1989	Europe	A61K31/41		
15.		EP 355 819	02/28/1990	Europe	C07C 275/42		
16.		EP 403 713	12/27/1990	Europe	C07F 7/08		
17.		WO 92/18475	10/29/1992	PCT	C07D 207/08		
18.		WO 95/20389	08/03/1995	PCT	A61K 31/535		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
19. Enclosed		Begue et al., "The International Journal for the Rapid Publication of Critical Reviews and Original Research Communications in Organic Chemistry and Related Disciplines, Especially Bio-organic Chemistry," Tetrahedron, 47:3207 (1991)
20. Enclosed		Brown et al., "Hydroboration. IV. A Study of the Relative Reactivities of Representative Functional Groups toward Diborane," J. Amer. Chem. Soc., 82:3866-3869 (1960)
21.		Conley et al., "Synthesis of the Cardiotonic Bemarinone, 5, 6-Dimethoxy-4-methyl-2(1H)-quinazolinone, Utilizing a Directed Metalation Approach," J. Het. Chem., 32:761 (1995)
22. Enclosed		Delmar et al., "A Sensitive New Substrate For Chymotrypsin," Analytical Biochemistry, 99:316-320 (1979)
23. Enclosed		Dess et al., "A Useful 12-I-5 Triacetoxyperiodinane (the Dess-Martin Periodinane) for the Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-I-5 Species," J. Amer. Chem. Soc., 113:7277-7287 (1991)

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 3 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	S02932/3A/US (31027/USA) (6794-000129/COE)	10/696,940
	APPLICANT	
	Daniel L. Flynn et al.	
	FILING DATE	GROUP
	October 30, 2003	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
24. Enclosed		Doherty et al., "Design and Synthesis of Potent, Selective, and Orally Active Fluorine-Containing Renin Inhibitors," J. Med. Chem., 35 (1):2-14 (1992)
25. Enclosed		Gaus et al., "Highly Selective Reducing Agents. Reduction of Nitrobenzene to Aniline in the Presence of Aldehydes, Alkyl Halides, and Acid Halides," Tetrahedron Letters, 29:5083-5086 (1988)
26. Enclosed		International Search Report, Written Opinion, and International Preliminary Examination Report from International Application No. PCT/US97/03736 (filed 3/19/1997)
27.		Liu et al., "The Herpes Simplex Virus 1 Gene Encoding a Protease Also Contains within Its Coding Domain the Gene Encoding the More Abundant Substrate," J. Virol., Vol. 65:5149-5156 (1991)
28.		Powers, J. C. and Harper, J. W. (1986) in <u>Proteinase Inhibitors: Research Monographs in Cell and Tissue Physiology</u> (Barrett, A. J. and Salvesen, G., eds.), vol. 12, pp. 55-152, Elsevier, Amsterdam
29. Enclosed		Prakash et al., "Fluoride-Induced Trifluoromethylation of Carbonyl Compounds with Trifluoromethyltrimethylsilane (TMS-CF ₃). A Trifluoromethide Equivalent," J. Amer. Chem. Soc., 111:393 (1989)
30.		Ries et al., "6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships," J. Med. Chem., 36:4040 (1993)
31.		Roizman, "Herpesviridae," In: Fields, ed. <u>Fields Virology</u> , 2, 3rd Ed., Lippincott-Raven: pages 2221-2224
32. Enclosed		Rylander, "Hydrogenation of Nitro Compounds," Hydrogenation Methods, Chap 8 (1985)
33. Enclosed		Spaete et al., "Insertion and deletion mutagenesis of the human cytomegalovirus genome," Proc. Nat. Acad. Sci., 84:7213-7217 (1987)
34. Enclosed		Thaisrivongs et al., "Design and Synthesis of Potent and Specific Renin Inhibitors Containing Difluorostatine, Difluorostatone, and Related Analogues," J. Med. Chem., 29:2080-2087 (1986)
35.		Webster's New World Dictionary of the American Language, "prophylactic," page 1168 (College ed. 1962)

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 4 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	S02932/3A/US (31027/USA) (6794-000129/COE)	10/696,940
	APPLICANT	
	Daniel L. Flynn et al.	
	FILING DATE	GROUP
	October 30, 2003	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
36. Enclosed		Welch et al., "Cytomegalovirus Assembly Protein Nested Gene Family: Four 3'-Coterminal Transcripts Encode Four In-Frame, Overlapping Proteins," Journal of Virology, 65:4091-4100 (1991)
37.		Welch et al., "A Herpesvirus Maturation Proteinase, Assemblin: Identification of its Gene, Putative Active Site Domain, and Cleavage Site," Proc. Natl. Acad. Sci. USA, 88:10792-10796 (1992)
38.		Wiley et al., "Peptidomimetics derived from natural products," Med. Res. Rev. 13:327-384 (1993)
39. Enclosed		Witkowski et al., "Total Synthesis of (+)-10,10-Difluorothromboxane A ₂ and Its 9,11 and 15 Stereoisomers," J. Amer. Chem. Soc., 114:8464 (1992)

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.